These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 20832123)

  • 1. Platelet [³H] paroxetine binding in female patients with borderline personality disorder and their sisters.
    Paris J; Laporte L; Russell J; Ng Ying Kin N; Guttman H
    Psychiatry Res; 2011 Mar; 186(1):76-9. PubMed ID: 20832123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affective lability in bipolar disorder and borderline personality disorder.
    Reich DB; Zanarini MC; Fitzmaurice G
    Compr Psychiatry; 2012 Apr; 53(3):230-7. PubMed ID: 21632042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder.
    Ng Ying Kin NM; Paris J; Schwartz G; Zweig-Frank H; Steiger H; Nair NP
    Psychopharmacology (Berl); 2005 Nov; 182(3):447-51. PubMed ID: 16052363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Symptoms of DSM IV borderline personality disorder in a nonclinical population of adolescents: study of a series of 35 patients].
    Chabrol H; Chouicha K; Montovany A; Callahan S
    Encephale; 2001; 27(2):120-7. PubMed ID: 11407263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Borderline psychopathology in the first-degree relatives of borderline and axis II comparison probands.
    Zanarini MC; Frankenburg FR; Yong L; Raviola G; Bradford Reich D; Hennen J; Hudson JI; Gunderson JG
    J Pers Disord; 2004 Oct; 18(5):439-47. PubMed ID: 15519954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopathology, childhood trauma, and personality traits in patients with borderline personality disorder and their sisters.
    Laporte L; Paris J; Guttman H; Russell J
    J Pers Disord; 2011 Aug; 25(4):448-62. PubMed ID: 21838561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of affective instability and UPPS impulsivity in borderline personality disorder features.
    Tragesser SL; Robinson RJ
    J Pers Disord; 2009 Aug; 23(4):370-83. PubMed ID: 19663657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is bulimia associated with borderline personality disorder? A controlled study.
    Pope HG; Frankenburg FR; Hudson JI; Jonas JM; Yurgelun-Todd D
    J Clin Psychiatry; 1987 May; 48(5):181-4. PubMed ID: 3571171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personality disorders and response to medication treatment in panic disorder: a 1-year naturalistic study.
    Marchesi C; De Panfilis C; Cantoni A; Fontò S; Giannelli MR; Maggini C
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1240-5. PubMed ID: 16678956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fear of harm, a possible phenotype of pediatric bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes.
    Papolos D; Mattis S; Golshan S; Molay F
    J Affect Disord; 2009 Nov; 118(1-3):28-38. PubMed ID: 19631388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yi-gan san for the treatment of borderline personality disorder: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashia M; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):150-4. PubMed ID: 17765378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Childhood abuse and platelet tritiated-paroxetine binding in bulimia nervosa: implications of borderline personality disorder.
    Steiger H; Léonard S; Kin NY; Ladouceur C; Ramdoyal D; Young SN
    J Clin Psychiatry; 2000 Jun; 61(6):428-35. PubMed ID: 10901341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A relationship between bipolar II disorder and borderline personality disorder?
    Benazzi F
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1022-9. PubMed ID: 18313825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of four measures to diagnose DSM-III-R borderline personality disorder in outpatients.
    Lewis SJ; Harder DW
    J Nerv Ment Dis; 1991 Jun; 179(6):329-37. PubMed ID: 2051147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced density of platelet-binding sites for [3H]paroxetine in remitted bulimic women.
    Steiger H; Richardson J; Israel M; Ng Ying Kin NM; Bruce K; Mansour S; Marie Parent A
    Neuropsychopharmacology; 2005 May; 30(5):1028-32. PubMed ID: 15841087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder.
    Teicher MH; Glod CA; Aaronson ST; Gunter PA; Schatzberg AF; Cole JO
    Psychopharmacol Bull; 1989; 25(4):535-49. PubMed ID: 2631134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of paroxetine for the treatment of depression in the context of HIV infection.
    Grassi B; Gambini O; Garghentini G; Lazzarin A; Scarone S
    Pharmacopsychiatry; 1997 Mar; 30(2):70-1. PubMed ID: 9131727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine versus placebo: a double-blind comparison in depressed patients.
    Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
    J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.